Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Test du traitement continu par rapport au traitement intermittent avec le médicament à l'étude zanubrutinib pour les patients âgés atteints d'un lymphome à cellules du manteau non traité auparavant

2 novembre 2026 mis à jour par: Alliance for Clinical Trials in Oncology

Un essai randomisé de phase 3 sur le traitement d'entretien continu ou intermittent avec le zanubrutinib comme traitement initial chez les patients âgés atteints de lymphome à cellules du manteau

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used in MCL, the current standard of care is to continue administering the drug indefinitely until disease progression. This continuous treatment comes with clinical as well as financial toxicity, which could be especially detrimental in older patients. For patients who achieve a CR after initial zanubrutinib plus rituximab therapy, it may be safe and equally effective to stop treatment and restart zanubrutinib upon disease progression rather than continuing indefinitely in previously untreated older adult patients with MCL.

Aperçu de l'étude

Description détaillée

PRIMARY OBJECTIVE:

I. To compare time to first progression or death (progression free survival [PFS]1) with continuous treatment (Arm A) and time to second progression or death (PFS2) with intermittent treatment that is restarted at first progression (Arm B).

KEY SECONDARY OBJECTIVE:

I. To compare overall survival between patients who achieve a complete remission (CR) with induction therapy subsequently treated with continuous treatment versus (vs.) intermittent treatment as part of maintenance therapy.

SECONDARY OBJECTIVES:

I. To determine overall response rate (ORR) and CR rate to induction therapy with zanubrutinib and rituximab in previously untreated MCL.

II. To determine adverse events during induction and post-induction in each study arm (Arm A and B) by Common Terminology Criteria for Adverse Events (CTCAE) 5.0.

III. To determine PFS1, event free survival (EFS) and overall survival (OS) in each study arm (A and B).

IV. To determine the overall response rate (ORR) and complete response rate (CR) after restarting zanubrutinib, following the first progression, in the intermittent treatment arm (Arm B).

V. To compare burden of symptomatic adverse events (AEs) as assessed by Patient-Reported Outcome Common Terminology Criteria for Adverse Events (PRO-CTCAE) between patients randomized to Arm A versus Arm B.

QUALITY OF LIFE PRIMARY OBJECTIVE:

I. To compare health-related quality of life (QOL) at 12 months post-randomization as assessed by the Functional Assessment of Cancer Therapy (FACT) Lymphoma Symptom Index-18 (FLYMSI-18) total score between patients randomized to Arm A versus Arm B.

QUALITY OF LIFE SECONDARY OBJECTIVES:

I. To compare health-related QOL at other time points as assessed by the FLYMSI-18 total score between patients randomized to Arm A versus Arm B.

II. To compare burden of symptomatic AEs as assessed by PRO-CTCAE between patients randomized to continuous (Arm A) versus intermittent (Arm B) zanubrutinib treatment.

QUALITY OF LIFE EXPLORATORY OBJECTIVES:

I. To compare the geriatric functional and cognitive PRO as assessed by Elderly Functional Index (ELFI) and Neurology (Neuro) QOL in Arm A versus Arm B.

II. To compare cognitive function at various time points as assessed by the Neuro-QOL between patients randomized to continuous (Arm A) versus intermittent (Arm B) zanubrutinib treatment.

EXPLORATORY OBJECTIVES:

I. To evaluate the completion rate of a lymphoma-specific patient assessment of life survey (PALS) with patient directed questions on life, health, and social determinants of health (SDH) and assess the impact of the survey collected data on outcomes for all enrolled patients (study arms A and B).

II. To evaluate minimal residual disease (MRD) in those patients who achieve a CR after induction therapy (arms A and B) and how detectable MRD status changes after continued therapy vs. discontinuation of therapy (i.e. arms A vs. B).

OUTLINE:

INDUCTION THERAPY: Patients receive zanubrutinib orally (PO) twice daily (BID) on days 1-28 of each cycle and rituximab intravenously (IV) on day 1 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. . Patients undergo bone marrow biopsy and fluciclovine F18 (FDG) positron emission tomography (PET)/ computed tomography (CT) or CT throughout the trial. Patients may also undergo esophagogastroduodenoscopy (EGD) and/or colonoscopy on study as clinically indicated. Patients may optionally undergo blood sample collection throughout the trial.

MAINTENANCE THERAPY: Patients achieving a CR after induction therapy are randomized to 1 of 2 arms.

ARM A: Patients receive zanubrutinib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days until first disease progression on study. Patients undergo CT or magnetic resonance imaging (MRI) or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial.

ARM B: Patients undergo observation until first disease progression and then receive zanubrutinib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days until second disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial and may undergo bone marrow biopsy on study.

After completion of study treatment, patients are followed within 30 days and every 6 months for 10 years.

Type d'étude

Interventionnel

Inscription (Estimé)

421

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Arkansas
      • Little Rock, Arkansas, États-Unis, 72205
        • Recrutement
        • University of Arkansas for Medical Sciences
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 501-686-8274
        • Chercheur principal:
          • Cesar Gentille
    • California
      • Beverly Hills, California, États-Unis, 90211
      • Duarte, California, États-Unis, 91010
        • Actif, ne recrute pas
        • City of Hope Comprehensive Cancer Center
      • Irvine, California, États-Unis, 92618
        • Actif, ne recrute pas
        • City of Hope at Irvine Lennar
      • Los Angeles, California, États-Unis, 90048
        • Recrutement
        • Cedars-Sinai Medical Center
        • Chercheur principal:
          • Justin M. Darrah
        • Contact:
    • Connecticut
      • Derby, Connecticut, États-Unis, 06418
        • Recrutement
        • Smilow Cancer Hospital-Derby Care Center
        • Chercheur principal:
          • Shalin Kothari
        • Contact:
      • Fairfield, Connecticut, États-Unis, 06824
        • Recrutement
        • Smilow Cancer Hospital Care Center-Fairfield
        • Chercheur principal:
          • Shalin Kothari
        • Contact:
      • Glastonbury, Connecticut, États-Unis, 06033
        • Recrutement
        • Smilow Cancer Hospital Care Center at Glastonbury
        • Chercheur principal:
          • Shalin Kothari
        • Contact:
      • Greenwich, Connecticut, États-Unis, 06830
        • Recrutement
        • Smilow Cancer Hospital Care Center at Greenwich
        • Chercheur principal:
          • Shalin Kothari
        • Contact:
      • Guilford, Connecticut, États-Unis, 06437
        • Recrutement
        • Smilow Cancer Hospital Care Center - Guilford
        • Chercheur principal:
          • Shalin Kothari
        • Contact:
      • Hartford, Connecticut, États-Unis, 06105
        • Recrutement
        • Smilow Cancer Hospital Care Center at Saint Francis
        • Chercheur principal:
          • Shalin Kothari
        • Contact:
      • New Haven, Connecticut, États-Unis, 06520
        • Recrutement
        • Yale University
        • Chercheur principal:
          • Shalin Kothari
        • Contact:
      • North Haven, Connecticut, États-Unis, 06473
        • Recrutement
        • Yale-New Haven Hospital North Haven Medical Center
        • Chercheur principal:
          • Shalin Kothari
        • Contact:
      • Stamford, Connecticut, États-Unis, 06902
        • Recrutement
        • Smilow Cancer Hospital Care Center at Long Ridge
        • Chercheur principal:
          • Shalin Kothari
        • Contact:
      • Torrington, Connecticut, États-Unis, 06790
        • Recrutement
        • Smilow Cancer Hospital-Torrington Care Center
        • Chercheur principal:
          • Shalin Kothari
        • Contact:
      • Trumbull, Connecticut, États-Unis, 06611
        • Recrutement
        • Smilow Cancer Hospital Care Center-Trumbull
        • Chercheur principal:
          • Shalin Kothari
        • Contact:
      • Waterbury, Connecticut, États-Unis, 06708
        • Recrutement
        • Smilow Cancer Hospital-Waterbury Care Center
        • Chercheur principal:
          • Shalin Kothari
        • Contact:
      • Waterford, Connecticut, États-Unis, 06385
        • Recrutement
        • Smilow Cancer Hospital Care Center - Waterford
        • Chercheur principal:
          • Shalin Kothari
        • Contact:
    • Delaware
      • Newark, Delaware, États-Unis, 19713
        • Recrutement
        • Helen F Graham Cancer Center
        • Chercheur principal:
          • Gregory A. Masters
        • Contact:
      • Newark, Delaware, États-Unis, 19713
        • Recrutement
        • Medical Oncology Hematology Consultants PA
        • Chercheur principal:
          • Gregory A. Masters
        • Contact:
    • Georgia
      • Albany, Georgia, États-Unis, 31701
        • Recrutement
        • Phoebe Putney Memorial Hospital
        • Chercheur principal:
          • Locke J. Bryan
        • Contact:
      • Atlanta, Georgia, États-Unis, 30322
        • Recrutement
        • Emory University Hospital/Winship Cancer Institute
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 404-778-1868
        • Chercheur principal:
          • Jonathon B. Cohen
      • Atlanta, Georgia, États-Unis, 30303
        • Recrutement
        • Grady Health System
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 404-778-1868
        • Chercheur principal:
          • Jonathon B. Cohen
      • Atlanta, Georgia, États-Unis, 30308
        • Recrutement
        • Emory University Hospital Midtown
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 888-946-7447
        • Chercheur principal:
          • Jonathon B. Cohen
      • Atlanta, Georgia, États-Unis, 30342
        • Recrutement
        • Emory Saint Joseph's Hospital
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 404-851-7115
        • Chercheur principal:
          • Jonathon B. Cohen
      • Augusta, Georgia, États-Unis, 30912
        • Recrutement
        • Augusta University Medical Center
        • Chercheur principal:
          • Locke J. Bryan
        • Contact:
      • Johns Creek, Georgia, États-Unis, 30097
        • Recrutement
        • Emory Johns Creek Hospital
        • Chercheur principal:
          • Jonathon B. Cohen
        • Contact:
    • Idaho
      • Boise, Idaho, États-Unis, 83712
        • Recrutement
        • Saint Luke's Cancer Institute - Boise
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
      • Boise, Idaho, États-Unis, 83706
        • Recrutement
        • Saint Alphonsus Cancer Care Center-Boise
        • Contact:
        • Chercheur principal:
          • Christopher M. Reynolds
      • Caldwell, Idaho, États-Unis, 83605
        • Recrutement
        • Saint Alphonsus Cancer Care Center-Caldwell
        • Contact:
        • Chercheur principal:
          • Christopher M. Reynolds
      • Coeur d'Alene, Idaho, États-Unis, 83814
        • Recrutement
        • Kootenai Health - Coeur d'Alene
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Fruitland, Idaho, États-Unis, 83619
        • Recrutement
        • Saint Luke's Cancer Institute - Fruitland
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
      • Meridian, Idaho, États-Unis, 83642
        • Recrutement
        • Saint Luke's Cancer Institute - Meridian
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
      • Nampa, Idaho, États-Unis, 83687
        • Recrutement
        • Saint Luke's Cancer Institute - Nampa
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
      • Nampa, Idaho, États-Unis, 83687
        • Recrutement
        • Saint Alphonsus Cancer Care Center-Nampa
        • Contact:
        • Chercheur principal:
          • Christopher M. Reynolds
      • Post Falls, Idaho, États-Unis, 83854
        • Recrutement
        • Kootenai Clinic Cancer Services - Post Falls
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Sandpoint, Idaho, États-Unis, 83864
        • Recrutement
        • Kootenai Clinic Cancer Services - Sandpoint
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
    • Illinois
      • Bloomington, Illinois, États-Unis, 61704
        • Recrutement
        • Illinois CancerCare-Bloomington
        • Contact:
        • Chercheur principal:
          • Bryan A. Faller
      • Canton, Illinois, États-Unis, 61520
        • Recrutement
        • Illinois CancerCare-Canton
        • Contact:
        • Chercheur principal:
          • Bryan A. Faller
      • Carthage, Illinois, États-Unis, 62321
        • Recrutement
        • Illinois CancerCare-Carthage
        • Contact:
        • Chercheur principal:
          • Bryan A. Faller
      • Chicago, Illinois, États-Unis, 60612
        • Recrutement
        • University of Illinois
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 312-355-3046
        • Chercheur principal:
          • Carlos Galvez
      • Chicago, Illinois, États-Unis, 60606
        • Recrutement
        • Alliance for Clinical Trials in Oncology
        • Chercheur principal:
          • Anne W. Beaven
        • Contact:
      • Danville, Illinois, États-Unis, 61832
        • Recrutement
        • Carle at The Riverfront
        • Chercheur principal:
          • Maria T. Grosse-Perdekamp
        • Contact:
      • Decatur, Illinois, États-Unis, 62526
        • Recrutement
        • Cancer Care Specialists of Illinois - Decatur
        • Chercheur principal:
          • Bryan A. Faller
        • Contact:
      • Decatur, Illinois, États-Unis, 62526
        • Recrutement
        • Decatur Memorial Hospital
        • Chercheur principal:
          • Bryan A. Faller
        • Contact:
      • Dixon, Illinois, États-Unis, 61021
        • Recrutement
        • Illinois CancerCare-Dixon
        • Chercheur principal:
          • Bryan A. Faller
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 815-285-7800
      • Effingham, Illinois, États-Unis, 62401
        • Recrutement
        • Carle Physician Group-Effingham
        • Contact:
        • Chercheur principal:
          • Maria T. Grosse-Perdekamp
      • Effingham, Illinois, États-Unis, 62401
        • Recrutement
        • Crossroads Cancer Center
        • Chercheur principal:
          • Bryan A. Faller
        • Contact:
      • Eureka, Illinois, États-Unis, 61530
        • Recrutement
        • Illinois CancerCare-Eureka
        • Contact:
        • Chercheur principal:
          • Bryan A. Faller
      • Evanston, Illinois, États-Unis, 60201
        • Recrutement
        • NorthShore University HealthSystem-Evanston Hospital
        • Chercheur principal:
          • Amy Y. Wang
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 847-570-2109
      • Galesburg, Illinois, États-Unis, 61401
        • Recrutement
        • Illinois CancerCare-Galesburg
        • Contact:
        • Chercheur principal:
          • Bryan A. Faller
      • Glenview, Illinois, États-Unis, 60026
        • Recrutement
        • NorthShore University HealthSystem-Glenbrook Hospital
        • Chercheur principal:
          • Amy Y. Wang
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 847-570-2109
      • Highland Park, Illinois, États-Unis, 60035
        • Recrutement
        • NorthShore University HealthSystem-Highland Park Hospital
        • Chercheur principal:
          • Amy Y. Wang
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 847-570-2109
      • Kewanee, Illinois, États-Unis, 61443
        • Recrutement
        • Illinois CancerCare-Kewanee Clinic
        • Contact:
        • Chercheur principal:
          • Bryan A. Faller
      • Macomb, Illinois, États-Unis, 61455
        • Recrutement
        • Illinois CancerCare-Macomb
        • Contact:
        • Chercheur principal:
          • Bryan A. Faller
      • Mattoon, Illinois, États-Unis, 61938
        • Recrutement
        • Carle Physician Group-Mattoon/Charleston
        • Contact:
        • Chercheur principal:
          • Maria T. Grosse-Perdekamp
      • Mount Vernon, Illinois, États-Unis, 62864
        • Recrutement
        • SSM Health Good Samaritan
        • Chercheur principal:
          • Jay W. Carlson
        • Contact:
      • O'Fallon, Illinois, États-Unis, 62269
        • Recrutement
        • Cancer Care Center of O'Fallon
        • Chercheur principal:
          • Bryan A. Faller
        • Contact:
      • Ottawa, Illinois, États-Unis, 61350
        • Recrutement
        • Illinois CancerCare-Ottawa Clinic
        • Contact:
        • Chercheur principal:
          • Bryan A. Faller
      • Pekin, Illinois, États-Unis, 61554
        • Recrutement
        • Illinois CancerCare-Pekin
        • Contact:
        • Chercheur principal:
          • Bryan A. Faller
      • Peoria, Illinois, États-Unis, 61615
        • Recrutement
        • Illinois CancerCare-Peoria
        • Contact:
        • Chercheur principal:
          • Bryan A. Faller
      • Peru, Illinois, États-Unis, 61354
        • Recrutement
        • Illinois CancerCare-Peru
        • Contact:
        • Chercheur principal:
          • Bryan A. Faller
      • Princeton, Illinois, États-Unis, 61356
        • Recrutement
        • Illinois CancerCare-Princeton
        • Contact:
        • Chercheur principal:
          • Bryan A. Faller
      • Shiloh, Illinois, États-Unis, 62269
        • Recrutement
        • Memorial Hospital East
        • Contact:
        • Chercheur principal:
          • Brad S. Kahl
      • Springfield, Illinois, États-Unis, 62702
        • Recrutement
        • Southern Illinois University School of Medicine
        • Chercheur principal:
          • Bryan A. Faller
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 217-545-7929
      • Springfield, Illinois, États-Unis, 62702
        • Recrutement
        • Springfield Clinic
        • Chercheur principal:
          • Bryan A. Faller
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 800-444-7541
      • Springfield, Illinois, États-Unis, 62781
        • Recrutement
        • Springfield Memorial Hospital
        • Chercheur principal:
          • Bryan A. Faller
        • Contact:
      • Urbana, Illinois, États-Unis, 61801
        • Recrutement
        • Carle Cancer Center
        • Contact:
        • Chercheur principal:
          • Maria T. Grosse-Perdekamp
      • Washington, Illinois, États-Unis, 61571
        • Recrutement
        • Illinois CancerCare - Washington
        • Contact:
        • Chercheur principal:
          • Bryan A. Faller
    • Indiana
      • Crown Point, Indiana, États-Unis, 46307
        • Recrutement
        • Northwest Cancer Center - Crown Point
        • Chercheur principal:
          • Maria T. Grosse-Perdekamp
        • Contact:
      • Dyer, Indiana, États-Unis, 46311
        • Recrutement
        • Northwest Oncology LLC
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 219-924-8178
        • Chercheur principal:
          • Maria T. Grosse-Perdekamp
      • Hobart, Indiana, États-Unis, 46342
        • Recrutement
        • Northwest Cancer Center - Hobart
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 219-947-1795
        • Chercheur principal:
          • Maria T. Grosse-Perdekamp
      • Hobart, Indiana, États-Unis, 46342
        • Recrutement
        • Saint Mary Medical Center
        • Chercheur principal:
          • Maria T. Grosse-Perdekamp
        • Contact:
      • Indianapolis, Indiana, États-Unis, 46312
        • Recrutement
        • Saint Catherine Hospital
        • Contact:
        • Chercheur principal:
          • Maria T. Grosse-Perdekamp
      • Munster, Indiana, États-Unis, 46321
        • Recrutement
        • The Community Hospital
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 219-836-3349
        • Chercheur principal:
          • Maria T. Grosse-Perdekamp
      • Munster, Indiana, États-Unis, 46321
        • Recrutement
        • Women's Diagnostic Center - Munster
        • Contact:
        • Chercheur principal:
          • Maria T. Grosse-Perdekamp
      • Valparaiso, Indiana, États-Unis, 46383
        • Recrutement
        • Northwest Cancer Center - Valparaiso
        • Chercheur principal:
          • Maria T. Grosse-Perdekamp
        • Contact:
    • Iowa
      • Ames, Iowa, États-Unis, 50010
        • Recrutement
        • Mary Greeley Medical Center
        • Chercheur principal:
          • Joseph J. Merchant
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-956-4132
      • Ames, Iowa, États-Unis, 50010
        • Recrutement
        • McFarland Clinic - Ames
        • Chercheur principal:
          • Joseph J. Merchant
        • Contact:
      • Ankeny, Iowa, États-Unis, 50023
        • Recrutement
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-241-3305
        • Chercheur principal:
          • Seema Harichand-Herdt
      • Boone, Iowa, États-Unis, 50036
        • Suspendu
        • McFarland Clinic - Boone
      • Carroll, Iowa, États-Unis, 51401
        • Recrutement
        • Saint Anthony Regional Hospital
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-689-7658
          • E-mail: sbenson@iora.org
        • Chercheur principal:
          • Seema Harichand-Herdt
      • Clive, Iowa, États-Unis, 50325
        • Recrutement
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-241-3305
        • Chercheur principal:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, États-Unis, 50314
        • Recrutement
        • Broadlawns Medical Center
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-282-2200
        • Chercheur principal:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, États-Unis, 50314
        • Recrutement
        • Mercy Medical Center - Des Moines
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-241-3305
        • Chercheur principal:
          • Richard L. Deming
      • Des Moines, Iowa, États-Unis, 50309
        • Recrutement
        • Iowa Methodist Medical Center
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-241-6727
        • Chercheur principal:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, États-Unis, 50309
        • Recrutement
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-241-3305
        • Chercheur principal:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, États-Unis, 50314
        • Recrutement
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-241-3305
        • Chercheur principal:
          • Seema Harichand-Herdt
      • Fort Dodge, Iowa, États-Unis, 50501
        • Recrutement
        • McFarland Clinic - Trinity Cancer Center
        • Chercheur principal:
          • Joseph J. Merchant
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-956-4132
      • Fort Dodge, Iowa, États-Unis, 50501
        • Recrutement
        • UI Healthcare Mission Cancer and Blood - Fort Dodge
        • Chercheur principal:
          • Seema Harichand-Herdt
        • Contact:
      • Iowa City, Iowa, États-Unis, 52242
        • Recrutement
        • University of Iowa/Holden Comprehensive Cancer Center
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 800-237-1225
        • Chercheur principal:
          • Eric Mou
      • Jefferson, Iowa, États-Unis, 50129
        • Suspendu
        • McFarland Clinic - Jefferson
      • Marshalltown, Iowa, États-Unis, 50158
        • Recrutement
        • McFarland Clinic - Marshalltown
        • Chercheur principal:
          • Joseph J. Merchant
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-956-4132
      • Waukee, Iowa, États-Unis, 50263
        • Recrutement
        • UI Health Care Mission Cancer and Blood - Waukee Clinic
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 515-241-3305
        • Chercheur principal:
          • Seema Harichand-Herdt
    • Kansas
      • Hays, Kansas, États-Unis, 67601
        • Recrutement
        • HaysMed
        • Chercheur principal:
          • Marc S. Hoffmann
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 785-623-5774
      • Kansas City, Kansas, États-Unis, 66160
        • Recrutement
        • University of Kansas Cancer Center
        • Chercheur principal:
          • Marc S. Hoffmann
        • Contact:
      • Lawrence, Kansas, États-Unis, 66044
        • Recrutement
        • Lawrence Memorial Hospital
        • Chercheur principal:
          • Marc S. Hoffmann
        • Contact:
      • Leavenworth, Kansas, États-Unis, 66048
        • Suspendu
        • Veteran Administration Eastern Kansas Healthcare
      • Olathe, Kansas, États-Unis, 66061
        • Recrutement
        • The University of Kansas Cancer Center - Olathe
        • Chercheur principal:
          • Marc S. Hoffmann
        • Contact:
      • Overland Park, Kansas, États-Unis, 66210
        • Recrutement
        • University of Kansas Cancer Center-Overland Park
        • Chercheur principal:
          • Marc S. Hoffmann
        • Contact:
      • Pittsburg, Kansas, États-Unis, 66762
        • Recrutement
        • Freeman Physician Group of Pittsburg
        • Chercheur principal:
          • Marc S. Hoffmann
        • Contact:
      • Salina, Kansas, États-Unis, 67401
        • Recrutement
        • Salina Regional Health Center
        • Chercheur principal:
          • Marc S. Hoffmann
        • Contact:
      • Topeka, Kansas, États-Unis, 66606
        • Recrutement
        • University of Kansas Health System Saint Francis Campus
        • Chercheur principal:
          • Marc S. Hoffmann
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 785-295-8000
      • Westwood, Kansas, États-Unis, 66205
        • Recrutement
        • University of Kansas Hospital-Westwood Cancer Center
        • Chercheur principal:
          • Marc S. Hoffmann
        • Contact:
    • Kentucky
      • Louisville, Kentucky, États-Unis, 40202
        • Recrutement
        • The James Graham Brown Cancer Center at University of Louisville
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 502-562-3429
        • Chercheur principal:
          • Hassaan Yasin
      • Louisville, Kentucky, États-Unis, 40245
        • Recrutement
        • UofL Health Medical Center Northeast
        • Contact:
        • Chercheur principal:
          • Hassaan Yasin
    • Michigan
      • Ann Arbor, Michigan, États-Unis, 48106
        • Recrutement
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
        • Contact:
        • Chercheur principal:
          • Christopher M. Reynolds
      • Bay City, Michigan, États-Unis, 48706
        • Recrutement
        • McLaren Cancer Institute-Bay City
        • Chercheur principal:
          • Dipenkumar Modi
        • Contact:
      • Brighton, Michigan, États-Unis, 48114
        • Recrutement
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
        • Contact:
        • Chercheur principal:
          • Christopher M. Reynolds
      • Brighton, Michigan, États-Unis, 48114
        • Recrutement
        • Trinity Health Medical Center - Brighton
        • Contact:
        • Chercheur principal:
          • Christopher M. Reynolds
      • Canton, Michigan, États-Unis, 48188
        • Recrutement
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
        • Contact:
        • Chercheur principal:
          • Christopher M. Reynolds
      • Canton, Michigan, États-Unis, 48188
        • Recrutement
        • Trinity Health Medical Center - Canton
        • Contact:
        • Chercheur principal:
          • Christopher M. Reynolds
      • Chelsea, Michigan, États-Unis, 48118
        • Recrutement
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
        • Contact:
        • Chercheur principal:
          • Christopher M. Reynolds
      • Chelsea, Michigan, États-Unis, 48118
      • Clarkston, Michigan, États-Unis, 48346
        • Recrutement
        • McLaren Cancer Institute-Clarkston
        • Chercheur principal:
          • Dipenkumar Modi
        • Contact:
      • Detroit, Michigan, États-Unis, 48201
        • Recrutement
        • Wayne State University/Karmanos Cancer Institute
        • Chercheur principal:
          • Dipenkumar Modi
        • Contact:
      • Farmington Hills, Michigan, États-Unis, 48334
        • Recrutement
        • Weisberg Cancer Treatment Center
        • Chercheur principal:
          • Dipenkumar Modi
        • Contact:
      • Farmington Hills, Michigan, États-Unis, 48336
        • Recrutement
        • Corewell Health Farmington Hills Hospital
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 248-551-7695
        • Chercheur principal:
          • Andrew A. Muskovitz
      • Flint, Michigan, États-Unis, 48503
        • Recrutement
        • Genesys Hurley Cancer Institute
        • Chercheur principal:
          • Christopher M. Reynolds
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 810-762-8038
          • E-mail: wstrong@ghci.org
      • Flint, Michigan, États-Unis, 48503
        • Recrutement
        • Hurley Medical Center
        • Chercheur principal:
          • Christopher M. Reynolds
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 810-762-8038
          • E-mail: wstrong@ghci.org
      • Flint, Michigan, États-Unis, 48532
        • Recrutement
        • McLaren Cancer Institute-Flint
        • Chercheur principal:
          • Dipenkumar Modi
        • Contact:
      • Flint, Michigan, États-Unis, 48503
        • Suspendu
        • Genesee Hematology Oncology PC
      • Flint, Michigan, États-Unis, 48503
        • Recrutement
        • Cancer Hematology Centers - Flint
        • Chercheur principal:
          • Christopher M. Reynolds
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 810-762-8038
          • E-mail: wstrong@ghci.org
      • Lansing, Michigan, États-Unis, 48912
        • Recrutement
        • University of Michigan Health - Sparrow Lansing
        • Chercheur principal:
          • Christopher M. Reynolds
        • Contact:
      • Lapeer, Michigan, États-Unis, 48446
        • Recrutement
        • McLaren Cancer Institute-Lapeer Region
        • Chercheur principal:
          • Dipenkumar Modi
        • Contact:
      • Livonia, Michigan, États-Unis, 48154
        • Recrutement
        • Trinity Health Saint Mary Mercy Livonia Hospital
        • Contact:
        • Chercheur principal:
          • Christopher M. Reynolds
      • Macomb, Michigan, États-Unis, 48044
        • Recrutement
        • Henry Ford Saint John Hospital - Macomb Medical
        • Chercheur principal:
          • Christopher M. Reynolds
        • Contact:
      • Mount Pleasant, Michigan, États-Unis, 48858
        • Recrutement
        • McLaren Cancer Institute-Central Michigan
        • Chercheur principal:
          • Dipenkumar Modi
        • Contact:
      • Petoskey, Michigan, États-Unis, 49770
        • Recrutement
        • McLaren Cancer Institute-Northern Michigan
        • Chercheur principal:
          • Dipenkumar Modi
        • Contact:
      • Pontiac, Michigan, États-Unis, 48341
        • Recrutement
        • Trinity Health Saint Joseph Mercy Oakland Hospital
        • Contact:
        • Chercheur principal:
          • Christopher M. Reynolds
      • Royal Oak, Michigan, États-Unis, 48073
        • Recrutement
        • Corewell Health William Beaumont University Hospital
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 248-551-7695
        • Chercheur principal:
          • Andrew A. Muskovitz
      • Saginaw, Michigan, États-Unis, 48604
        • Suspendu
        • Oncology Hematology Associates of Saginaw Valley PC
      • Saginaw, Michigan, États-Unis, 48601
        • Recrutement
        • MyMichigan Medical Center Saginaw
        • Contact:
        • Chercheur principal:
          • Christopher M. Reynolds
      • Tawas City, Michigan, États-Unis, 48764
        • Recrutement
        • MyMichigan Medical Center Tawas
        • Contact:
        • Chercheur principal:
          • Christopher M. Reynolds
      • Troy, Michigan, États-Unis, 48085
        • Recrutement
        • Corewell Health Beaumont Troy Hospital
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 248-551-7695
        • Chercheur principal:
          • Andrew A. Muskovitz
      • West Branch, Michigan, États-Unis, 48661
        • Suspendu
        • Saint Mary's Oncology/Hematology Associates of West Branch
      • Ypsilanti, Michigan, États-Unis, 48106
        • Recrutement
        • Huron Gastroenterology PC
        • Contact:
        • Chercheur principal:
          • Christopher M. Reynolds
      • Ypsilanti, Michigan, États-Unis, 48197
        • Recrutement
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
        • Contact:
        • Chercheur principal:
          • Christopher M. Reynolds
    • Minnesota
      • Bemidji, Minnesota, États-Unis, 56601
      • Brainerd, Minnesota, États-Unis, 56401
        • Recrutement
        • Essentia Health Saint Joseph's Medical Center
        • Contact:
        • Chercheur principal:
          • Bret E. Friday
      • Coon Rapids, Minnesota, États-Unis, 55433
        • Recrutement
        • Mercy Hospital
        • Contact:
        • Chercheur principal:
          • Yan Ji
      • Deer River, Minnesota, États-Unis, 56636
        • Recrutement
        • Essentia Health - Deer River Clinic
        • Contact:
        • Chercheur principal:
          • Bret E. Friday
      • Duluth, Minnesota, États-Unis, 55805
        • Recrutement
        • Essentia Health Cancer Center
        • Contact:
        • Chercheur principal:
          • Bret E. Friday
      • Edina, Minnesota, États-Unis, 55435
        • Recrutement
        • Minnesota Oncology - Edina
        • Contact:
        • Chercheur principal:
          • Yan Ji
      • Hibbing, Minnesota, États-Unis, 55746
        • Recrutement
        • Essentia Health Hibbing Clinic
        • Chercheur principal:
          • Bret E. Friday
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 218-786-3308
      • Maplewood, Minnesota, États-Unis, 55109
        • Recrutement
        • Saint John's Hospital - Healtheast
        • Contact:
        • Chercheur principal:
          • Yan Ji
      • Minneapolis, Minnesota, États-Unis, 55407
        • Recrutement
        • Abbott-Northwestern Hospital
        • Contact:
        • Chercheur principal:
          • Yan Ji
      • Minneapolis, Minnesota, États-Unis, 55415
        • Recrutement
        • Hennepin County Medical Center
        • Contact:
        • Chercheur principal:
          • Yan Ji
      • Saint Cloud, Minnesota, États-Unis, 56303
        • Recrutement
        • Coborn Cancer Center at Saint Cloud Hospital
        • Contact:
        • Chercheur principal:
          • Donald J. Jurgens
      • Saint Louis Park, Minnesota, États-Unis, 55416
        • Recrutement
        • Park Nicollet Clinic - Saint Louis Park
        • Contact:
        • Chercheur principal:
          • Yan Ji
      • Saint Paul, Minnesota, États-Unis, 55101
        • Recrutement
        • Regions Hospital
        • Contact:
        • Chercheur principal:
          • Yan Ji
      • Saint Paul, Minnesota, États-Unis, 55102
        • Recrutement
        • United Hospital
        • Contact:
        • Chercheur principal:
          • Yan Ji
      • Sandstone, Minnesota, États-Unis, 55072
        • Recrutement
        • Essentia Health Sandstone
        • Contact:
        • Chercheur principal:
          • Bret E. Friday
      • Virginia, Minnesota, États-Unis, 55792
        • Recrutement
        • Essentia Health Virginia Clinic
        • Contact:
        • Chercheur principal:
          • Bret E. Friday
      • Woodbury, Minnesota, États-Unis, 55125
        • Recrutement
        • Minnesota Oncology Hematology PA-Woodbury
        • Contact:
        • Chercheur principal:
          • Yan Ji
    • Missouri
      • Cape Girardeau, Missouri, États-Unis, 63703
        • Recrutement
        • Saint Francis Medical Center
        • Chercheur principal:
          • Bryan A. Faller
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 573-334-2230
          • E-mail: sfmc@sfmc.net
      • Chesterfield, Missouri, États-Unis, 63017
        • Recrutement
        • Saint Luke's Hospital
        • Chercheur principal:
          • Mark J. Fesler
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 314-205-6936
      • City of Saint Peters, Missouri, États-Unis, 63376
        • Recrutement
        • Siteman Cancer Center at Saint Peters Hospital
        • Contact:
        • Chercheur principal:
          • Brad S. Kahl
      • Creve Coeur, Missouri, États-Unis, 63141
        • Recrutement
        • Siteman Cancer Center at West County Hospital
        • Contact:
        • Chercheur principal:
          • Brad S. Kahl
      • Kansas City, Missouri, États-Unis, 64154
        • Recrutement
        • University of Kansas Cancer Center - North
        • Chercheur principal:
          • Marc S. Hoffmann
        • Contact:
      • Kansas City, Missouri, États-Unis, 64128
        • Recrutement
        • Kansas City Veterans Affairs Medical Center
        • Chercheur principal:
          • Suman Kambhampati
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 800-525-1483
      • Kansas City, Missouri, États-Unis, 64108
        • Recrutement
        • University Health Truman Medical Center
        • Chercheur principal:
          • Marc S. Hoffmann
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 816-404-4375
      • Kansas City, Missouri, États-Unis, 64116
        • Recrutement
        • University of Kansas Cancer Center - Briarcliff
        • Chercheur principal:
          • Marc S. Hoffmann
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 913-588-3671
      • Lee's Summit, Missouri, États-Unis, 64064
        • Recrutement
        • University of Kansas Cancer Center - Lee's Summit
        • Chercheur principal:
          • Marc S. Hoffmann
        • Contact:
      • North Kansas City, Missouri, États-Unis, 64116
        • Suspendu
        • University of Kansas Cancer Center at North Kansas City Hospital
      • Springfield, Missouri, États-Unis, 65804
        • Recrutement
        • Mercy Hospital Springfield
        • Chercheur principal:
          • Jay W. Carlson
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 417-269-4520
      • Springfield, Missouri, États-Unis, 65807
        • Recrutement
        • CoxHealth South Hospital
        • Chercheur principal:
          • Jay W. Carlson
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 417-269-4520
      • St Louis, Missouri, États-Unis, 63110
        • Recrutement
        • Washington University School of Medicine
        • Contact:
        • Chercheur principal:
          • Brad S. Kahl
      • St Louis, Missouri, États-Unis, 63128
        • Recrutement
        • Mercy Hospital South
        • Chercheur principal:
          • Jay W. Carlson
        • Contact:
      • St Louis, Missouri, États-Unis, 63129
        • Recrutement
        • Siteman Cancer Center-South County
        • Contact:
        • Chercheur principal:
          • Brad S. Kahl
      • St Louis, Missouri, États-Unis, 63136
        • Recrutement
        • Siteman Cancer Center at Christian Hospital
        • Contact:
        • Chercheur principal:
          • Brad S. Kahl
    • Montana
      • Anaconda, Montana, États-Unis, 59711
        • Recrutement
        • Community Hospital of Anaconda
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Billings, Montana, États-Unis, 59101
        • Recrutement
        • Billings Clinic Cancer Center
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Bozeman, Montana, États-Unis, 59715
        • Recrutement
        • Bozeman Health Deaconess Hospital
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Great Falls, Montana, États-Unis, 59405
        • Recrutement
        • Benefis Sletten Cancer Institute
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Kalispell, Montana, États-Unis, 59901
        • Recrutement
        • Logan Health Medical Center
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
      • Missoula, Montana, États-Unis, 59804
        • Recrutement
        • Community Medical Center
        • Chercheur principal:
          • John M. Schallenkamp
        • Contact:
    • Nebraska
      • Bellevue, Nebraska, États-Unis, 68123
        • Recrutement
        • Nebraska Medicine-Bellevue
        • Chercheur principal:
          • Julie M. Vose
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 402-559-6941
          • E-mail: unmcrsa@unmc.edu
      • Kearney, Nebraska, États-Unis, 68845
        • Recrutement
        • Fred and Pamela Buffett Cancer Center - Kearney
        • Chercheur principal:
          • Julie M. Vose
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 402-559-6941
          • E-mail: unmcrsa@unmc.edu
      • Omaha, Nebraska, États-Unis, 68198
        • Recrutement
        • University of Nebraska Medical Center
        • Chercheur principal:
          • Julie M. Vose
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 402-559-6941
          • E-mail: unmcrsa@unmc.edu
      • Omaha, Nebraska, États-Unis, 68118
        • Recrutement
        • Nebraska Medicine-Village Pointe
        • Chercheur principal:
          • Julie M. Vose
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 402-559-5600
    • New Hampshire
      • Lebanon, New Hampshire, États-Unis, 03756
        • Recrutement
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
        • Contact:
        • Chercheur principal:
          • Charles Gaulin
    • New York
      • Buffalo, New York, États-Unis, 14263
        • Recrutement
        • Roswell Park Cancer Institute
        • Contact:
        • Chercheur principal:
          • Chelsea Peterson
      • Camillus, New York, États-Unis, 13031
        • Recrutement
        • Hematology Oncology Associates of CNY at Camillus
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 315-472-7504
        • Chercheur principal:
          • Steven M. Duffy
      • East Syracuse, New York, États-Unis, 13057
        • Recrutement
        • Hematology Oncology Associates of Central New York-East Syracuse
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 315-472-7504
        • Chercheur principal:
          • Steven M. Duffy
      • Mineola, New York, États-Unis, 11501
        • Recrutement
        • NYU Langone Hospital - Long Island
        • Chercheur principal:
          • Peter Martin
        • Contact:
      • New York, New York, États-Unis, 10016
        • Recrutement
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
        • Chercheur principal:
          • Peter Martin
        • Contact:
      • New York, New York, États-Unis, 10065
        • Recrutement
        • NYP/Weill Cornell Medical Center
        • Chercheur principal:
          • Jia Ruan
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 212-746-1848
      • Rochester, New York, États-Unis, 14642
        • Recrutement
        • University of Rochester
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 585-275-5830
        • Chercheur principal:
          • Paul M. Barr
      • Webster, New York, États-Unis, 14580
    • North Carolina
      • Chapel Hill, North Carolina, États-Unis, 27599
        • Recrutement
        • UNC Lineberger Comprehensive Cancer Center
        • Contact:
        • Chercheur principal:
          • Anne W. Beaven
      • Durham, North Carolina, États-Unis, 27710
        • Recrutement
        • Duke University Medical Center
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 888-275-3853
        • Chercheur principal:
          • Matthew S. McKinney
    • North Dakota
      • Bismarck, North Dakota, États-Unis, 58501
      • Fargo, North Dakota, États-Unis, 58122
      • Fargo, North Dakota, États-Unis, 58103
        • Recrutement
        • Essentia Health Cancer Center-South University Clinic
        • Contact:
        • Chercheur principal:
          • Bret E. Friday
      • Fargo, North Dakota, États-Unis, 58122
    • Ohio
      • Columbus, Ohio, États-Unis, 43210
        • Recrutement
        • Ohio State University Comprehensive Cancer Center
        • Contact:
        • Chercheur principal:
          • David A. Bond
    • Oklahoma
      • Lawton, Oklahoma, États-Unis, 73505
        • Recrutement
        • Cancer Centers of Southwest Oklahoma Research
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 877-231-4440
        • Chercheur principal:
          • Taha Al-Juhaishi
      • Oklahoma City, Oklahoma, États-Unis, 73104
        • Recrutement
        • University of Oklahoma Health Sciences Center
        • Contact:
        • Chercheur principal:
          • Taha Al-Juhaishi
      • Tulsa, Oklahoma, États-Unis, 74146
        • Recrutement
        • Oklahoma Cancer Specialists and Research Institute-Tulsa
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 918-505-3200
        • Chercheur principal:
          • Mark B. Jennings
    • Oregon
      • Newberg, Oregon, États-Unis, 97132
        • Recrutement
        • Providence Newberg Medical Center
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
      • Ontario, Oregon, États-Unis, 97914
        • Recrutement
        • Saint Alphonsus Cancer Care Center-Ontario
        • Contact:
        • Chercheur principal:
          • Christopher M. Reynolds
      • Oregon City, Oregon, États-Unis, 97045
        • Recrutement
        • Providence Willamette Falls Medical Center
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
      • Portland, Oregon, États-Unis, 97213
        • Recrutement
        • Providence Portland Medical Center
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
      • Portland, Oregon, États-Unis, 97225
        • Recrutement
        • Providence Saint Vincent Medical Center
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
    • Rhode Island
      • Providence, Rhode Island, États-Unis, 02903
        • Recrutement
        • Rhode Island Hospital
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 401-444-1488
        • Chercheur principal:
          • Adam J. Olszewski
      • Westerly, Rhode Island, États-Unis, 02891
        • Recrutement
        • Smilow Cancer Hospital Care Center - Westerly
        • Chercheur principal:
          • Shalin Kothari
        • Contact:
    • South Carolina
      • Boiling Springs, South Carolina, États-Unis, 29316
        • Recrutement
        • Prisma Health Cancer Institute - Spartanburg
        • Chercheur principal:
          • Suzanne R. Fanning
        • Contact:
      • Charleston, South Carolina, États-Unis, 29425
        • Recrutement
        • Medical University of South Carolina
        • Contact:
        • Chercheur principal:
          • Katherine Antel
      • Easley, South Carolina, États-Unis, 29640
        • Recrutement
        • Prisma Health Cancer Institute - Easley
        • Chercheur principal:
          • Suzanne R. Fanning
        • Contact:
      • Greenville, South Carolina, États-Unis, 29605
        • Recrutement
        • Prisma Health Cancer Institute - Faris
        • Chercheur principal:
          • Suzanne R. Fanning
        • Contact:
      • Greenville, South Carolina, États-Unis, 29605
        • Recrutement
        • Prisma Health Cancer Institute - Butternut
        • Chercheur principal:
          • Suzanne R. Fanning
        • Contact:
      • Greenville, South Carolina, États-Unis, 29615
        • Recrutement
        • Prisma Health Cancer Institute - Eastside
        • Chercheur principal:
          • Suzanne R. Fanning
        • Contact:
      • Greer, South Carolina, États-Unis, 29650
        • Recrutement
        • Prisma Health Cancer Institute - Greer
        • Chercheur principal:
          • Suzanne R. Fanning
        • Contact:
      • Seneca, South Carolina, États-Unis, 29672
        • Recrutement
        • Prisma Health Cancer Institute - Seneca
        • Chercheur principal:
          • Suzanne R. Fanning
        • Contact:
    • South Dakota
      • Sioux Falls, South Dakota, États-Unis, 57104
        • Recrutement
        • Sanford Cancer Center Oncology Clinic
        • Chercheur principal:
          • Daniel Almquist
        • Contact:
      • Sioux Falls, South Dakota, États-Unis, 57117-5134
    • Utah
      • Salt Lake City, Utah, États-Unis, 84112
        • Recrutement
        • Huntsman Cancer Institute/University of Utah
        • Contact:
        • Chercheur principal:
          • Harsh Shah
    • Vermont
      • Saint Johnsbury, Vermont, États-Unis, 05819
        • Recrutement
        • Dartmouth Cancer Center - North
        • Contact:
        • Chercheur principal:
          • Charles Gaulin
    • Virginia
      • Richmond, Virginia, États-Unis, 23235
        • Recrutement
        • VCU Massey Cancer Center at Stony Point
        • Contact:
        • Chercheur principal:
          • Bruce O. Hough
      • Richmond, Virginia, États-Unis, 23298
        • Recrutement
        • VCU Massey Comprehensive Cancer Center
        • Chercheur principal:
          • Bruce O. Hough
        • Contact:
    • Washington
      • Edmonds, Washington, États-Unis, 98026
        • Recrutement
        • Swedish Cancer Institute-Edmonds
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
      • Issaquah, Washington, États-Unis, 98029
        • Recrutement
        • Swedish Cancer Institute-Issaquah
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
      • Seattle, Washington, États-Unis, 98122
        • Recrutement
        • Swedish Medical Center-First Hill
        • Chercheur principal:
          • Alison K. Conlin
        • Contact:
    • Wisconsin
      • Appleton, Wisconsin, États-Unis, 54911
        • Recrutement
        • ThedaCare Regional Cancer Center
        • Contact:
        • Chercheur principal:
          • Yazhini Vallatharasu
      • Appleton, Wisconsin, États-Unis, 54911
        • Recrutement
        • ThedaCare Regional Medical Center - Appleton
        • Contact:
        • Chercheur principal:
          • Yazhini Vallatharasu
      • Ashland, Wisconsin, États-Unis, 54806
        • Recrutement
        • Duluth Clinic Ashland
        • Contact:
        • Chercheur principal:
          • Bret E. Friday
      • Eau Claire, Wisconsin, États-Unis, 54701
      • Johnson Creek, Wisconsin, États-Unis, 53038
        • Recrutement
        • University of Wisconsin Carbone Cancer Center - Johnson Creek
        • Chercheur principal:
          • Priyanka Pophali
        • Contact:
      • La Crosse, Wisconsin, États-Unis, 54601
        • Recrutement
        • Gundersen Lutheran Medical Center
        • Contact:
        • Chercheur principal:
          • Michael O. Ojelabi
      • Madison, Wisconsin, États-Unis, 53792
        • Recrutement
        • University of Wisconsin Carbone Cancer Center - University Hospital
        • Chercheur principal:
          • Priyanka Pophali
        • Contact:
      • Madison, Wisconsin, États-Unis, 53718
        • Recrutement
        • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
        • Chercheur principal:
          • Priyanka Pophali
        • Contact:
      • Marshfield, Wisconsin, États-Unis, 54449
      • Milwaukee, Wisconsin, États-Unis, 53226
        • Recrutement
        • Medical College of Wisconsin
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 414-805-3666
        • Chercheur principal:
          • Mehdi Hamadani
      • Minocqua, Wisconsin, États-Unis, 54548
      • Mukwonago, Wisconsin, États-Unis, 53149
        • Recrutement
        • ProHealth D N Greenwald Center
        • Contact:
        • Chercheur principal:
          • Timothy R. Wassenaar
      • New Berlin, Wisconsin, États-Unis, 53151
        • Recrutement
        • Froedtert and MCW Moorland Reserve Health Center
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 414-805-0505
        • Chercheur principal:
          • Mehdi Hamadani
      • Oconomowoc, Wisconsin, États-Unis, 53066
        • Recrutement
        • ProHealth Oconomowoc Memorial Hospital
        • Chercheur principal:
          • Timothy R. Wassenaar
        • Contact:
          • Site Public Contact
          • Numéro de téléphone: 262-928-7878
      • Rice Lake, Wisconsin, États-Unis, 54868
      • Stevens Point, Wisconsin, États-Unis, 54482
      • Waukesha, Wisconsin, États-Unis, 53188
        • Recrutement
        • UW Cancer Center at ProHealth Care
        • Chercheur principal:
          • Timothy R. Wassenaar
        • Contact:
      • Weston, Wisconsin, États-Unis, 54476

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

60 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • • Histologically confirmed mantle cell lymphoma with cyclin D1 (BCL1) expression by immunohistochemical stains and/or evidence of CCND1 rearrangement or t(11;14)(q13;q32) as confirmed by the enrolling center (such as by fluorescence in situ hybridization [FISH], polymerase chain reaction [PCR]/sequencing, karyotype). Patients with cyclin D1 and/or t(11;14) negative mantle cell lymphoma with an expression profile suggesting a diagnosis of mantle cell lymphoma [MCL] such as SOX11 expression are also eligible

    • Any stage allowed (stage I-IV)

      • Patient must have at least one objective measurable disease parameter by PET or CT. Measurable disease in the liver is required if the liver is the only site of lymphoma OR bone marrow involvement by MCL
      • Steroids for management of mantle cell lymphoma are allowed up to a dose of prednisone 100mg/day (or equivalent) for up to 7 days prior to registration
      • No prior systemic treatment for mantle cell lymphoma
      • No prior radiation treatment for stage I MCL
      • No prior exposure to a BTK inhibitor or anti-CD20 monoclonal antibody
      • No prior stem cell transplant
      • Age >= 70 years OR age >= 60 to < 70 years with comorbidities precluding autologous stem cell transplantation (autoSCT) including at least one of the following: a) cardiac ejection fraction (EF) <= 45%, b) diffusing capacity for carbon monoxide <= 60% predicted; c) creatinine clearance < 70 but >= 30ml/minute (min); d) Eastern Cooperative Oncology Group (ECOG) performance status of 2, which poses an unacceptable risk of toxicity for high-dose therapy and stem cell transplantation; or e) Cumulative Illness Rating Scales (CIRS) total score > 6
      • ECOG Performance Status 0-2
      • Absolute neutrophil count (ANC) >= 750/mm^3 (without growth factor support within 7 days)
      • Platelet count >= 75,000/mm^3 (or >= 50,000/mm^3 if thrombocytopenia is due to lymphoma) without growth factor support or transfusion within 7 days
      • Creatinine clearance >= 30 mL/ min determined by either: a) Estimation using the Cockcroft-Gault equation or b) Measurement by nuclear medicine scan or 24 hour urine collection
      • Total bilirubin =< 1.5 x upper limit of normal (ULN) (unless documented Gilbert's syndrome)
      • Aspartate transferase (AST) / alanine transaminase (ALT) =< 3 x ULN
      • Patients should not be considered candidates for stem cell transplant or must have declined a stem cell transplant strategy
      • No clinically significant cardiovascular disease including the following
    • Unstable angina within 3 months before registration

    • New York Heart Association class III or IV congestive heart failure

    • History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes)

    • Known QT correction formula (QTcF) > 480 msecs based on Fredericia's formula (unless pacemaker in place)

    • History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place

      • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
      • No active Hepatitis B or Hepatitis C infection. Patients with prior hepatitis B virus (HBV) exposure (positive HBV core antibody and/or surface antigen) are eligible if they have no detectable viral load, and are taking appropriate prophylactic antiviral therapy to prevent reactivation. Patients with history of hepatitis C virus (HCV) are eligible if they have an undetectable HCV viral load
      • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
      • No history of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention
      • No history of stroke or intracranial hemorrhage within 6 months prior to registration
      • No disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction. Patient must be able to swallow pills
      • Potential trial participants should have recovered from major surgery
      • No vaccination with a live vaccine within 35 days prior to registration
      • No hypersensitivity to zanubrutinib or rituximab or any of the other ingredients of the study drugs
      • Patients on strong CYP3A4 inhibitors must discontinue the drug for 14 days prior to registration on the study.
      • Patients on strong CYP3A4 inducers must discontinue the drug 14 days prior to registration.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Induction therapy (Zanubrutinib, rituximab)

Patients receive zanubrutinib PO and rituximab IV on study. Patients undergo bone marrow biopsy and FDG PET/CT or CT throughout the trial. Patients may also undergo EDG and/or colonoscopy on study as clinically indicated. Patients may optionally undergo blood sample collection throughout the trial.

Undergo blood sample collection

Given IV

Undergo CT

Autres noms:
  • Scanner
  • Tomodensitométrie

Undergo MRI

Autres noms:
  • IRM

Ancillary studies

Undergo PET

Autres noms:
  • ANIMAUX

Undergo colonoscopy

Undergo observation

Undergo EGD

Autres noms:
  • EGD

Given PO

undergo bone marrow biopsy

Given IV

Expérimental: Arm A (Zanubrutinib)

Patients receive zanubrutinib PO until first disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial.

Undergo blood sample collection

Undergo CT

Autres noms:
  • Scanner
  • Tomodensitométrie

Undergo MRI

Autres noms:
  • IRM

Ancillary studies

Undergo PET

Autres noms:
  • ANIMAUX

Undergo colonoscopy

Undergo observation

Undergo EGD

Autres noms:
  • EGD

Given PO

undergo bone marrow biopsy

Given IV

Comparateur actif: ARM B (Observation)

Patients undergo observation until first disease progression and then receive zanubrutinib PO until second disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial.

Undergo blood sample collection

Undergo CT

Autres noms:
  • Scanner
  • Tomodensitométrie

Undergo MRI

Autres noms:
  • IRM

Ancillary studies

Undergo PET

Autres noms:
  • ANIMAUX

Undergo colonoscopy

Undergo observation

Undergo EGD

Autres noms:
  • EGD

Given PO

undergo bone marrow biopsy

Given IV

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Progression-free survival (PFS) 1 (Arm A)
Délai: Time from randomization until the earlier of first progression or death from any cause, assessed up to 10 years

Hazard ratios on the treatment effect will be estimated using a stratified cox proportional hazards model, stratified on age and mantle cell lymphoma (MCL) International Prognostic Index (IPI) score. The primary analysis for non-inferiority will be based on an intent-to-treat (ITT) analysis and will include all randomized patients in the analyses, regardless of eligibility or treatment status. Sensitivity analyses will also be done in an ancillary manner to evaluate and compare our endpoints using a modified ITT approach, and exclude from the analysis those classified as ineligible as well as those who withdraw right after randomization prior to any treatment/observation monitoring.

Time from randomization until the earlier of first progression or death from any cause, assessed up to 10 years
Progression-free survival (PFS) 2 (Arm B)
Délai: Time from randomization until the earlier of second progression or death from any cause, assessed up to 10 years

Hazard ratios on the treatment effect will be estimated using a stratified cox proportional hazards model, stratified on age and MCL IPI score. The primary analysis for non-inferiority will be based on an ITT analysis and will include all randomized patients in the analyses, regardless of eligibility or treatment status. Sensitivity analyses will also be done in an ancillary manner to evaluate and compare our endpoints using a modified ITT approach, and exclude from the analysis those classified as ineligible as well as those who withdraw right after randomization prior to any treatment/observation monitoring.

Time from randomization until the earlier of second progression or death from any cause, assessed up to 10 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Overall survival (OS) (Arms A and B)
Délai: Time from randomization until death from any cause, assessed up to 10 years

Kaplan-Meier methodology will be used to estimate the distributions of OS by treatment arm and log-rank test statistics will be used to compare these distributions between the two treatment arms. Cox Proportional Hazards models may be used to further evaluate covariates of interest with OS, including assessment of treatment effects when adjusting for other known risk factors in the model.

Time from randomization until death from any cause, assessed up to 10 years
Incidence of adverse events
Délai: Up to 10 years

Will be evaluated and captured using the CTCAE 5.0, where the type and severity grade of each adverse event will be collected and tabulated within each of the treatment arms. Perceived attribution to study treatment will also be captured.

The analysis population for this secondary endpoint will include all patients who are registered and randomized on the study and receive at least one dose of study treatment. Adverse events will be monitored continuously throughout the course of the study as well as analyzed at the time of the final primary endpoint analysis.

Summary statistics and frequency tables will be used to describe the distributions of adverse events. Rates of adverse events occurring in compared across the treatment arms with chi-squared tests Tolerability will also be evaluated, summarizing rates of dose delays or modifications, reasons patients end treatment, and time to end of active treatment.

Up to 10 years
Overall response rate (ORR, complete + partial remission)
Délai: up to 10 years

Will be assessed using Lugano criteria. ORR to induction is defined as the number of patients with complete or partial remission at the end of induction divided by the number of patients who receive at least one dose of the induction regimen. ORR to restart of zanubrutinib is only defined for Arm B, as the number of patients with complete or partial remission after restart of zanubrutinib divided by the number of patients that restart zanubrutinib after first disease progression following randomization. The frequencies and rates of tumor response categories will be summarized by treatment arm for response to induction as well as response to restart of zanubrutinib (Arm B only). ORR to induction and ORR to restart of zanubrutinib (Arm B only) with 95% exact binomial confidence intervals will be calculated by treatment arm. To compare the association of treatment arm and ORR to induction, chi-squared or Fisher's Exact test will be used, whichever is more appropriate at final analysis.

up to 10 years
Complete response rate (CR)
Délai: Up to 10 years

Will be assessed using Lugano criteria. CR to induction is defined as the number of patients with complete remission at the end of induction divided by the number of eligible patients who receive at least one dose of the induction regimen. CR to restart of zanubrutinib is only defined for Arm B, as the number of patients with complete remission after restart of zanubrutinib divided by the number of eligible patients that restart zanubrutinib after first disease progression following randomization. CR to induction and CR to restart of zanubrutinib (Arm B patients only) with 95% exact binomial confidence intervals will be calculated by treatment arm. To compare the association of treatment arm and CR to induction, chi-squared or Fisher's Exact test will be used, whichever is more appropriate at the time of the final analysis.

Up to 10 years
Event-free survival (EFS) 1
Délai: Time from randomization (Arms A and B) until the earlier of first progression, start of an alternative MCL therapy, or death from any cause, assessed up to 10 years.

For EFS1, patients without an event will be censored at the last known clinical assessment. Any patient who goes to transplant will be censored at the last known clinical assessment prior to transplant. Kaplan-Meier methodology will be used to estimate the distribution of EFS. Cox Proportional Hazards models may be used to further evaluate covariates of interest with EFS.

Time from randomization (Arms A and B) until the earlier of first progression, start of an alternative MCL therapy, or death from any cause, assessed up to 10 years.
Event-free survival (EFS) 2
Délai: Time from randomization (Arm B) until the earlier of second progression, start of an alternative MCL therapy, or death from any cause, assessed up to 10 years.

For EFS2, patients without an event will be censored at the last known clinical assessment. Any patient who goes to transplant will be censored at the last known clinical assessment prior to transplant. Kaplan-Meier methodology will be used to estimate the distribution of EFS. Cox Proportional Hazards models may be used to further evaluate covariates of interest with EFS.

Time from randomization (Arm B) until the earlier of second progression, start of an alternative MCL therapy, or death from any cause, assessed up to 10 years.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

20 octobre 2023

Achèvement primaire (Estimé)

31 août 2038

Achèvement de l'étude (Estimé)

31 août 2038

Dates d'inscription aux études

Première soumission

26 juillet 2023

Première soumission répondant aux critères de contrôle qualité

26 juillet 2023

Première publication (Réel)

4 août 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

3 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

2 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner